Novo Nordisk reported to be preparing US launch of four-dose Wegovy FlexTouch pen

Novo Nordisk is preparing to launch a multi-dose Wegovy FlexTouch pen in the United States, according to reporting published August 8, 2026, by the newsletter On The Pen, which cited multiple credible sources and said FDA records show the device is already approved ^[1]. Novo Nordisk has not publicly announced a launch date or pricing, and no launch press release had been issued as of September 2026.

Wegovy is semaglutide. The FlexTouch presentation contains 9.6 mg of semaglutide in 3 mL and is designed to deliver four labeled doses of 2.4 mg ^[1][2].

What changes about the device

Injectable Wegovy in the US is currently sold as a box of four disposable pens. Each pen is used for one injection and then discarded ^[1]. With FlexTouch, a patient keeps one pen for about four weeks and attaches a new disposable needle for each weekly injection ^[1]. The report noted that FlexTouch is the same general multi-dose pen platform Americans already see with Ozempic, another semaglutide product ^[1].

The Wegovy prescribing information lists FlexTouch as a 9.6 mg/3 mL (3.2 mg/mL) solution in a single-patient-use pen that delivers four 2.4 mg/0.75 mL doses ^[2]. The label's June 2026 revision added a warning headed "Never Share WEGOVY FlexTouch Between Patients," which says the pen should not be shared even if the needle is changed ^[2]. Single-dose pens at 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg and 7.2 mg, along with single-dose syringes, remain part of the product lineup ^[2].

The report said the launch applies specifically to the 2.4 mg dose, with lower strengths not expected to be included at first ^[1]. In the label, 2.4 mg once weekly is the usual recommended maintenance dosage for Wegovy injection ^[2]. The report described the maintenance dose and the cash-pay channel as the logical place to start ^[1].

Several details have not been disclosed. The report raised the question of whether the FlexTouch pen will be priced and discounted the same way as the existing box, but did not answer it ^[1]. It also said a physician could prescribe the higher-dose flexible pen for a patient using a lower dose as a way to refill less often, and noted that doing so would go against the label and package insert ^[1]. The label describes the pen only as delivering four 2.4 mg doses ^[2].

The report also said Novo Nordisk does not have the 45-day refill requirement that Eli Lilly uses ^[1].

Why it matters for patients

For people on the 2.4 mg maintenance dose, the change is mostly about hardware, not the medicine. The drug, the strength and the once-weekly schedule stay the same ^[2]. What changes is the number of devices: one pen for roughly four weeks instead of four complete pens, with a new needle for each injection ^[1]. That means less refrigerator space and less to throw away, according to the report ^[1].

Patients on lower Wegovy doses would not get that option at first, because the initial launch is described as covering only 2.4 mg ^[1]. Dosing instructions in the label still call for titration through lower strengths before reaching maintenance ^[2].

Cost and coverage are the open questions. Whether the FlexTouch pen costs the same as the current box, and how insurers and pharmacy benefit managers treat it, has not been reported ^[1]. Neither has a launch date.

What happens next

The August 8, 2026 report said Novo Nordisk was preparing to launch the pen "in the coming weeks" and that the FDA had already cleared the device ^[1]. No specific date, price or distribution details have been announced. The prescribing information that lists FlexTouch is dated June 2026 ^[2].